Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-12-03
- Target Recruit Count
- 55
- Registration Number
- NCT04824131
- Locations
- 🇺🇬
MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda
🇿🇦Ward 21 CRS, Johannesburg, Gauteng, South Africa
🇿🇼Spilhaus CRS, Harare, Zimbabwe
A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya
- Conditions
- HIV Infections
- Interventions
- Biological: Env-C Plasmid DNABiological: HIV Env gp145 C.6980 proteinDrug: Rehydragel®Drug: Placebo (IM)Drug: Placebo (TCl)
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-03-26
- Target Recruit Count
- 143
- Registration Number
- NCT04826094
- Locations
- 🇰🇪
Kenya Medical Research Institute/Walter Reed Project, Clinical Research Centre, Off Hospital Road, Kericho, Kenya
Daratumumab and Belatacept for Desensitization
- Conditions
- Highly Sensitized Prospective Kidney Transplant Recipients
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 15
- Registration Number
- NCT04827979
- Locations
- 🇺🇸
University of California at San Francisco Medical Center, San Francisco, California, United States
The Effect of Helminth Infection Plus COVID-19 Infection on the Immune Response and Intestinal Microorganisms
- Conditions
- COVID-19
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2025-04-25
- Target Recruit Count
- 1500
- Registration Number
- NCT04813328
- Locations
- 🇮🇳
National Institute for Research in Tuberculosis - International Centers for Excellence in Research (NIRT-ICER), Chennai, Tamilnadu, India
A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized With Moderna COVID-19 Vaccine
- Conditions
- SARS-CoV-2 Infection
- Interventions
- Biological: Moderna COVID-19 Vaccine
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2023-08-02
- Target Recruit Count
- 1923
- Registration Number
- NCT04811664
- Locations
- 🇺🇸
Charles Drew University, Los Angeles, California, United States
🇺🇸The Hope Clinic of the Emory Vaccine Center CRS, Decatur, Georgia, United States
🇺🇸Stony Brook University, Stony Brook, New York, United States
Safety and Survival of Genetically Modified White Blood Cells in HIV-infected Twins The Gemini Study
- Conditions
- HIV
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 32
- Registration Number
- NCT04799483
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Systems Biology of Early Atopy
- Conditions
- Atopic DermatitisFood AllergyAllergic Diseases
- First Posted Date
- 2021-03-15
- Last Posted Date
- 2025-05-16
- Target Recruit Count
- 2500
- Registration Number
- NCT04798079
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination
- Conditions
- InfluenzaCOVID-19
- First Posted Date
- 2021-03-12
- Last Posted Date
- 2024-10-18
- Target Recruit Count
- 150
- Registration Number
- NCT04794829
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in Naïve and Previously Vaccinated Adults
- Conditions
- COVID-19COVID-19 Immunisation
- Interventions
- Biological: mRNA-1273Biological: mRNA-1273.351
- First Posted Date
- 2021-03-05
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 135
- Registration Number
- NCT04785144
- Locations
- 🇺🇸
The Hope Clinic of Emory University, Decatur, Georgia, United States
🇺🇸Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States
🇺🇸Cincinnati Children's Hospital Medical Center Vaccine Research Center, Cincinnati, Ohio, United States
DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia
- Conditions
- Staphylococcal Bacteraemia
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 200
- Registration Number
- NCT04775953
- Locations
- 🇺🇸
Corewell Health - Infectious Disease, Royal Oak, Michigan, United States
🇺🇸University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
🇺🇸University of California Davis Medical Center - Internal Medicine - Infectious Disease, Sacramento, California, United States